For media queries, please contact:
Rachel Steinhardt, Director of Communications
[+1] 212 450 1582 - Business hours, EST (GMT -5 hours)
Email: Rachel Steinhardt
News
May 03, 2012
THE LUDWIG INSTITUTE FOR CANCER RESEARCH ANNOUNCES LAUNCH OF ITEOS THERAPEUTICS SA
New Company to Focus on Developing Novel Immunotherapy Compounds for Cancer Treatment
NEW YORK, NY, May 3, 2012 – The Ludwig Institute for Cancer Research (LICR) announced today the launch of a private biotechnology enterprise, iTeos Therapeutics SA, to develop a novel pre-clinical pipeline of immunomodulators to stimulate the immune system’s ability to attack cancer. Founded by LICR with the de Duve Institute at the Université catholique de Louvain (UCL), iTeos is led by a team experienced in tumor immunology, immunotherapy, drug discovery, business development and entrepreneurship. iTeos is the ninth new company formed based on innovative cancer research discoveries licensed from LICR.
April 16, 2012
HOW USEFUL IS WHOLE GENOME SEQUENCING TO PREDICT DISEASE?
Few diseases have strong enough genetic components to make sequencing a solid way to assess individual risk
By Katherine Harmon | Monday, April 2, 2012
A $1,000 genome sequence is close to being available. What will your sequence tell you about your actual risk for certain diseases?
Many companies advertise a laundry list of disease risks associated with your genes. But your genome is unlikely to reveal whether or not you will actually get one of these conditions, according to a study published online April 2 in Science Translational Medicine.
